In a troubling revelation, recent statistics indicate that only 3.5% of urgent referrals for breast cancer specialists in Northern Ireland met the crucial two-week appointment target. This alarming figure, reported by the Department of Health (DoH), shows that merely 183 out of 5,309 patients referred for suspected breast cancer between July and September 2025 were actually seen within the designated 14-day timeframe.
The health minister acknowledged these numbers as reflective of what he termed an "early stage in the transition to our new regional breast assessment service." However, he emphasized that significant work remains to ensure timely patient care. Mike Nesbitt highlighted in his statement that this target has historically not been achieved in Northern Ireland, which prompted the introduction of a new healthcare system aimed at improving outcomes.
In his comments, he noted some positive shifts, mentioning that from October to December 2025, the health service created an additional 928 urgent appointment slots, resulting in a reduction of the regional breast assessment waiting list from 12 weeks in September to approximately seven weeks by mid-December.
Nevertheless, the quarter's statistics reveal further concerns: out of 6,194 new referrals for suspected breast cancer, only 2,699 patients actually received treatment. Of those, a disappointing 30%—or just 430 individuals—began their treatment within the recommended 62 days following an urgent GP referral, despite a government target that aims for at least 95%.
In this same timeframe, 2,499 patients (which constitutes 81%) commenced their first treatment within 31 days after a decision to treat, following urgent referrals. While this represents an improvement in both the number and percentage of treated patients compared to the previous quarter, it still falls short of the government's ambitious goal of 98%.
Nesbitt pointed out that the newly implemented service model and the introduction of the Encompass digital system had a noticeable impact on referral times during July to September 2025. He explained that these delays are anticipated short-term effects, with long-term benefits expected from the reform.
However, these disheartening statistics have drawn criticism from health advocates. Naser Turubi, the Director of Cancer Research UK, characterized the figures as unacceptable and called for “concerted action” to tackle these challenges directly. He stressed the necessity for more investment alongside a robust plan to enhance clinical capacity, thereby safeguarding patients from potential harm.
So, what does this mean for the future of cancer care in Northern Ireland? As the healthcare system grapples with these pressing issues, the question remains: how can we ensure that all patients receive the timely and effective treatment they deserve? We invite you to share your thoughts and engage in this critical conversation.
